Alteplase
Top View
- Abbokinase, Activase, Alteplase, Cathflo, Urokinase, Win-Kinase, Streptokinase, Drotrecogin Alfa, Anistreplase, Tenecteplase
- Acute Stroke Management Evidence Tables Acute Antiplatelet Therapy
- Administering Intravenous Alteplase (Tissue Plasminogen Activator [Tpa])
- Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: a Systematic Review of the Available Evidence
- Tpa for Stroke – Potential Benefit, Risk and Alternatives
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- Acute Ischemic Stroke EARLY MANAGEMENT of ACUTE ISCHEMIC STROKE
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Antithrombotic Therapy in Patients with Acute Coronary Syndromes
- The Safety and Efficacy of Heparin and Nadroparin Compared to Placebo
- 1346 Cardiovascular Drugs Membrane-Stabilising Activity
- For Your Acute Ischemic Stroke (AIS) Patients
- Scientific Rationale for the Inclusion and Exclusion Criteria For
- Targeting Coagulation Activation in Severe COVID-19 Pneumonia: Lessons from Bacterial Pneumonia and Sepsis
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
- ANTICOAGULANT, THROMBOLYTIC, and ANTI-PLATELET DRUGS
- Guidelines for ATC Classification and DDD Assignment 2021
- Effect of Low-Dose Intracoronary Alteplase During Primary